Progression of antimicrobial therapy against antimicrobial resistance innovated by maximized therapeutic effect of beta-lactams.

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K17467
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 54030:Infectious disease medicine-related
• Research Institution: Kumamoto University
• Principal Investigator: Oda Kazutaka 熊本大学, 病院, 薬剤師 (00753328)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: 抗菌薬 / 治療薬物モニタリング / TDM / 薬剤耐性 / antimicrobial resistance / 薬物動態 / pharmacokinetics

Outline of Final Research Achievements

Beta-lactam antibiotics, known for their high safety profile, may achieve therapeutic effects even against pathogens deemed resistant by conventional standards by maintaining their concentrations within a therapeutic range. This study aims to evaluate the therapeutic outcomes and safety of beta-lactam antibiotics through therapeutic drug monitoring (TDM), ensuring their concentrations remain within the effective range. The results demonstrate the potential of TDM to maximize the therapeutic effects of beta-lactam antibiotics such as meropenem, cefepime, and cefiderocol, while avoiding adverse events and reducing costs.

Free Research Field

臨床薬物動態学

Academic Significance and Societal Importance of the Research Achievements

薬剤耐性菌を回避するためには抗菌薬の適正使用は欠かせない。適正使用のためには抗菌薬の体内濃度を適正化し、確実に治癒に導くことが必要である。そのために必要な抗菌薬の体内の動きはいまだ十分に解明されていない。本研究は、臨床研究により３種類の抗菌薬の体内での動きを評価したところ、抗菌薬の使用開始時に考慮するべき因子（血液透析、腎臓の機能など）を明らかにするとともに、さらには抗菌薬の血液中濃度を測定することで、不要に過剰な量を回避する必要性を示した。